NURO - ヌロメトリックス （NeuroMetrix Inc.）

NeuroMetrix (NURO) stock fell ~3% after the company reported a decline in Q2 revenue and a widened net loss.Revenues fell -3.4% Y/Y to to $2.13M Y/Y

NeuroMetrix, Inc. (NASDAQ:NASDAQ:NURO) Q2 2022 Earnings Conference Call July 21, 2022 08:00 ET Company Participants Thomas Higgins - Senior Vice President and Chief Financial Officer Shai…

NeuroMetrix press release (NURO): Q2 GAAP EPS of -$0.17.Revenue of $2.1M (-5.0% Y/Y).

WOBURN, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and six months period ended June 30, 2022. The Company''s mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices.

WOBURN, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 second quarter financial results before the opening of the market on July 21, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on July 21, 2022 to discuss its financial results as well as business developments affecting the Company.

NeuroMetrix (NURO) stock fell ~3% after the company reported a decline in Q2 revenue and a widened net loss.Revenues fell -3.4% Y/Y to to $2.13M Y/Y

NeuroMetrix, Inc. (NASDAQ:NASDAQ:NURO) Q2 2022 Earnings Conference Call July 21, 2022 08:00 ET Company Participants Thomas Higgins - Senior Vice President and Chief Financial Officer Shai…

NeuroMetrix press release (NURO): Q2 GAAP EPS of -$0.17.Revenue of $2.1M (-5.0% Y/Y).

WOBURN, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and six months period ended June 30, 2022. The Company''s mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices.

WOBURN, Mass., July 14, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 second quarter financial results before the opening of the market on July 21, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on July 21, 2022 to discuss its financial results as well as business developments affecting the Company.

NeuroMetrix, Inc. (NASDAQ:NASDAQ:NURO) Q1 2022 Earnings Conference Call April 26, 2022 08:00 ET Company Participants Thomas Higgins - Senior Vice President and Chief Financial Officer Shai…

NeuroMetrix press release (NURO): Q1 GAAP EPS of -$0.14.Revenue of $2.3M (+6.5% Y/Y).The gross margin rate was 77.9% in Q1 2022 versus 73.3% in Q1 2021.The Company ended the quarter…

WOBURN, Mass., April 26, 2022 (GLOBE NEWSWIRE) — NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2022. The Company’s mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices. Highlights: Q1 2022 revenue of … The post NeuroMetrix Reports Q1 2022 Financial Results appeared first on ForexTV .

WOBURN, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 first quarter financial results before the opening of the market on April 26, 2022. The Company will host a conference call at 8:00 a.m., Eastern Time on April 26, 2022 to discuss its financial results as well as business developments affecting the Company.

NeuroMetrix Inc''s (NASDAQ: NURO ) Quell wearable neuromodulation technology will be evaluated for fibromyalgia-like syndrome in individuals with post-acute COVID-19 syndrome (PACS, or "long COVID"). Quell is an advanced, non-invasive neuromodulation technology covered by 22 U.S. utility patents and numerous … Full story available on Benzinga.com